Page 41 - John More News Today : Breaking News, Live Updates & Top Stories | Vimarsana

8698345 A playback facility will be available from May 5, 2021 at 1330 EDT / 1830 BST - May 12, 2021 at 1330 EDT / 1830 BST.  Access details for the playback facility are as follows: Confirmation Code: 8698345 | US: + 1 917 677 7532 | UK: +44 (0) 333 300 9785 | Ireland : +353 (1) 553 8777. About Amryt Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.  Amryt comprises a strong and growing portfolio of commercial and development assets.   ...

  Notes to Editors Emmerson's primary focus is on developing the Khemisset project ("Khemisset" or the "Project") located in Northern Morocco.  The Project has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K 2O and significant exploration potential with an accelerated development pathway targeting a low capex, high margin mine. Khemisset is perfectly located to capitalise on the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. This unique positioning means the Project will receive a premium netback pr...

  Tlou Energy is focused on delivering Power solutions to Botswana and southern Africa to alleviate some of the chronic power shortage in the region.  Tlou is currently developing projects using gas and plans to combine this with solar power to provide a cleaner base load power source.   Botswana has a significant energy shortage and generally relies on imported power and diesel generation to fulfil its power requirements.  Tlou's Lesedi Power Project provides investors with access to a compelling opportunity to displace expensive, carbon intensive diesel and impo...

Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights DUBLIN, Ireland, and Boston MA, March 11, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that subscription rights relating to warrants to acquire 283,389 Ordinary Shares (the “Warrants”) have been exercised. In order to satisfy the exercise of the Warrants, the Company on 11 March 2021 issued 283,389 o...

Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Remuneration Committee has approved the grant of 3,431,350 share options (" Options") to subscribe for ordinary shares in the Company (" Shares") under the Employee Share Option Plan 2019 (the " Plan") to Joe Wiley, CEO, and Rory Nealon, CFO, detail...